Predictive value of 0.35 T magnetic resonance imaging radiomic features in stereotactic ablative body radiotherapy of pancreatic cancer: A pilot study.
MR image guided radiotherapy
MRI
imaging biomarkers
pancreatic cancer
radiomics
stereotactic body radiotherapy
texture analysis
Journal
Medical physics
ISSN: 2473-4209
Titre abrégé: Med Phys
Pays: United States
ID NLM: 0425746
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
01
11
2019
revised:
31
03
2020
accepted:
06
04
2020
pubmed:
25
4
2020
medline:
15
5
2021
entrez:
25
4
2020
Statut:
ppublish
Résumé
The aim of this study was to evaluate the potential and feasibility of radiomic features extracted from low field strength (0.35 T) magnetic resonance images (MRIs) in predicting treatment response for patients with pancreatic cancer undergoing stereotactic body radiotherapy (SBRT). Twenty patients with unresected, non-metastatic pancreatic ductal adenocarcinoma (PDAC) were enrolled, all of whom received neoadjuvant chemotherapy followed by five-fraction MR-guided SBRT with a radiation dose range of 33-50 Gy. For each patient, five daily setup scans were acquired from a hybrid 0.35 T MRI/radiotherapy unit. Tumor heterogeneity quantified with radiomic features extracted from the gross tumor volume (GTV) was averaged over the course of treatment. Random forest (RF) and adaptive least absolute shrinkage and selection operator (LASSO) classification models were constructed to identify radiomics features predictive of treatment response. Predictive capability of the top-performing features was then evaluated using the receiver operating characteristic area under curve (AUC) obtained using leave-one-out cross-validation. Half of the 20 patients showed response to treatment, defined by tumor regression on histopathology or tumor response on follow-up dynamic contrast-enhanced computed tomography (CT). The most predictive features selected by the RF method were GLCM energy and GLSZM gray-level variance. The RF-based model achieved an AUC = 0.81 with a 95% confidence interval of [0.594 to 1] The LASSO algorithm selected GLCM energy as the only predictive feature, achieving an AUC = 0.81 with 95% confidence interval of [0.596 to 1]. The findings of this study suggest that radiomic features extracted during MR-guided SBRT may contain predictive information about response of PDAC patients to treatment. Using the images acquired during treatment of PDAC patients supports continued expansion of radiomic analysis based on low field strength MR images and may hold the potential for providing timely indications of response to treatment.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3682-3690Informations de copyright
© 2020 American Association of Physicists in Medicine.
Références
Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Can Res. 2014;74:2913-2921.
Garcea G, Dennison AR, Pattenden CJ, Neal CP, Sutton CD, Berry DP. Survival following curative resection for pancreatic ductal adenocarcinoma. A systematic review of the literature. JOP: J Pancreas. 2008;9:99-132.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7-34.
Mellon EA, Jin WH, Frakes JM, et al. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy. Acta oncologica (Stockholm, Sweden). 2017;56:391-397.
Hoyer M, Roed H, Sengelov L, et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol. 2005;76:48-53.
Schellenberg D, Kim J, Christman-Skieller C, et al. Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2011;81:181-188.
El-Bared N, Portelance L, Spieler BO, et al. Dosimetric benefits and practical pitfalls of daily online adaptive mri-guided stereotactic radiation therapy for pancreatic cancer. Pract Radiat Oncol. 2019;9:e46-e54.
Bruynzeel AME, Lagerwaard FJ. The role of biological dose-escalation for pancreatic cancer. Clin Transl Radiat Oncol. 2019;18:128-130.
Rudra S, Jiang N, Rosenberg SA, et al. Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. Cancer Med. 2019;8:2123-2132.
Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278:563-577.
Aerts H, Velazquez ER, Leijenaar RTH, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014;5:8.
Liu J, Mao Y, Li Z, et al. Use of texture analysis based on contrast-enhanced MRI to predict treatment response to chemoradiotherapy in nasopharyngeal carcinoma. J Magn Reson Imaging. 2016;44:445-455.
Avanzo M, Stancanello J, El Naqa I. Beyond imaging: the promise of radiomics. Physica Med. 2017;38:122-139.
Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer. 2012;48:441-446.
Jeong WK, Jamshidi N, Felker ER, Raman SS, Lu DS. Radiomics and radiogenomics of primary liver cancers. Clin Mol Hepatol. 2018;25:21-29.
Amin MB, Edge S, Greene F. AJCC Cancer Staging Manual, 8th edn. Basel: Springer International Publishing, American Joint Commission on Cancer; 2017.
Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2017;15:1028-1061.
Chapman BC, Gleisner A, Rigg D, et al. Perioperative and survival outcomes following neoadjuvant FOLFIRINOX versus gemcitabine abraxane in patients with pancreatic adenocarcinoma. JOP: J Pancreas. 2018;19:75-85.
Chatterjee D, Katz MH, Rashid A, et al. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer. 2012;118:3182-3190.
Schwartz LH, Litiere S, de Vries E, et al. mRECIST 1.1-update and clarification: from the mRECIST committee. Eur J Cancer. 2016;62:132-137.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised mRECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-247.
Vallières M. A radiomics model from joint FDG-PET and MRI texture features for the prediction of lun metastases in soft-tissue sarcomas of the extremities. Phys Med Biol. 2015;60:5471-5496.
Collewet G, Strzelecki M, Mariette F. Influence of MRI acquisition protocols and image intensity normalization methods on texture classification. Magn Reson Imaging. 2004;22:81-91.
Hall EL, Kruger RP, Dwyer SJ, Hall DL, Mclaren RW, Lodwick GS. A Survey of preprocessing and feature extraction techniques for radiographic images. IEEE Trans Comput. 1971;C-20:1032-1044.
Haralick RM, Shanmugam K, Dinstein IH. Textural features for image classification. IEEE Trans Syst Man Cybern. 1973;SMC3:610-621.
Thibault G, Fertil B, Navarro C, et al. Texture indexes and gray level size zone matrix application to cell. Nuclei Classification; 2009.
Haralick RM. Statistical and structural approaches to texture. Proc IEEE. 1979;67:786-804.
Amadasun M, King R. Textural features corresponding to textural properties. IEEE Trans Syst Man Cybernet. 1989;19:1264-1274.
Kwon D, Reis IM, Breto AL, et al. Classification of suspicious lesions on prostate multiparametric MRI using machine learning. Vol 5: SPIE; 2018.
Breiman L. Random forests. Mach Learn. 2001;45:5-32.
Zou H. The adaptive lasso and its oracle properties. J Am Statist Ass. 2006;101:1418-1429.
Liaw AWM. Classificaiton and regression by randomforest. R News. 2002;2:18-22.
Jerome Feidman TH,Robert T. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33:1-22.
Stoyanova R, Takhar M, Tschudi Y, et al. Prostate cancer radiomics and the promise of radiogenomics. Transl Cancer Res. 2016;5:432-447.
Yang F, Ford JC, Dogan N, et al. Magnetic resonance imaging (MRI)-based radiomics for prostate cancer radiotherapy. Transl Androl Urol. 2018;7:445-458.
van Timmeren JE, Leijenaar RTH, van Elmpt W, et al. Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images. Radiother Oncol. 2017;123:363-369.
Mahon RN, Hugo GD, Weiss E. Repeatability of texture features derived from magnetic resonance and computed tomography imaging and use in predictive models for non-small cell lung cancer outcome. Phys Med Biol. 2019;64:145007.
Wang G, He L, Yuan C, Huang Y, Liu Z, Liang C. Pretreatment MR imaging radiomics signatures for response prediction to induction chemotherapy in patients with nasopharyngeal carcinoma. Eur J Radiol. 2018;98:100-106.
Katz MHG, Fleming JB, Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118:5749-5756.
Yang F, Dogan N, Stoyanova R, Ford JC. Evaluation of radiomic texture feature error due to MRI acquisition and reconstruction: a simulation study utilizing ground truth. Phys Medica-Eur J Med Phys. 2018;50:26-36.
Boldrini L, Cusumano D, Chiloiro G, et al. Delta radiomics for rectal cancer response prediction with hybrid 0.35 T magnetic resonance-guided radiotherapy (MRgRT): a hypothesis-generating study for an innovative personalized medicine approach. Radiol Med (Torino). 2018;124:145-153.
Ford J, Dogan N, Yong L, Yang F. Quantitative radiomics: impact of pulse sequence parameter selection on MRI-based textural features of the brain. Contrast Media Mol Imaging. 2018;2018:1-9.
Kumar V, Gu YH, Basu S, et al. Radiomics: the process and the challenges. Magn Reson Imaging. 2012;30:1234-1248.
Yang F, Young L, Yang Y. Quantitative imaging: erring patterns in manual delineation of PET-imaged lung lesions. Radiother Oncol. 2019141:78-85.
Mori M, Benedetti G, Partelli S, et al. CT radiomic features of pancreatic neuroendocrine neoplasms (panNEN) are robust against delineation uncertainty. Physica Med. 2019;57:41-46.
Wang ZJ, Behr S, Consunji MV, et al. Early response assessment in pancreatic ductal adenocarcinoma through integrated PET/MRI. Am J Roentgenol. 2018;211:1010-1019.
Fave X, Zhang LF, Yang JZ, et al. Delta-radiomics features for the prediction of patient outcomes in non-small cell lung cancer. Sci Rep. 2017;7:11.
Jeong J, Wang LY, Ji B, et al. Machine-learning based classification of glioblastoma using delta-radiomic features derived from dynamic susceptibility contrast enhanced magnetic resonance images. Quant Imaging Med Surg. 2019;9:1201-1213.